

CURRICULUM VITAE

Jeffrey S. Turner, MD

4676 Admiralty Way, Suite 101

Marina del Rey, CA 90292

T: 310 827 7707

E: jeffrey@prostateoncology.com

Licensure	Medical Board of California, 2006, A94409
Certifications	American Board of Internal Medicine, 2006 American Board of Medical Oncology, 2009
NPI	1205855913
DEA	BT9813507

EDUCATION:

Fellowship	Medical Oncology, 2007-2009 Medical University of South Carolina Charleston, SC
Residency	Internal Medicine, 2003-2006 University of British Columbia Vancouver, BC
Medical School	Memorial University of Newfoundland, 1999-2003
College/University	University of Southern California, 1993-1996 Biological Sciences, B.A., cum laude. 1 st student to graduate from 3-year accelerated science program Dean's Scholar, Golden State Scholar, 'Scions Scholar
High School:	Los Alamitos, 1989-1993. Rank 1 of 540.
Present Employment	Prostate Oncology Specialists, Inc., Marina del Rey, CA December 2012 – present Compassionate Oncology Medical Group, Century City, CA June 2009 – October 2012 Presbyterian Intercommunity Hospital, Whittier, CA (Hospitalist) January 2007 – June 2007 South Coast Medical Center, Laguna Beach, CA (Hospitalist) July 2006 – December 2006
Society Memberships	American Society of Clinical Oncology American Society of Hematology American College of Physicians

Research Positions

UCLA, Staff Research Associate, Immunology/Infectious Diseases
June 2000 – August 2000

Consolidated Laboratory Services, Molecular Biology
October 1998 – July 1999

UCLA, Staff Research Associate, Immunology/Infectious Diseases
August 1996 – October 1998

PUBLICATIONS

Scholz, Mark C., S. Yep, C. Kelly, Khang N. Chau, Jeffrey S. Turner, and Richard Y. Lam. Phase I trial of sipuleucel-T combined with ipilimumab (SIP1P1) in progressive M-CRPC. Abstract. *Journal of Clinical Oncology* 34 (2016).

Almeida, Fabio, Steven Finkelstein, Larry Bans, Mark Scholz, Richard Lam, and Jeffrey Turner. Performance Characteristics and Influence of PSA Value/Kinetics on Carbon-11 Acetate PET/CT Imaging in Biochemical Relapse of Prostate Cancer. Presentation at the International Prostate Cancer Update 2016.

Scholz, Mark C., Richard Y. Lam, Jeffrey S. Turner, and Clifford U. Felarca. Y-90 Resin Castrate-Resistant Prostate Cancer with Liver Metastasis. Poster at the Gastrointestinal Cancer Symposium 2016.

Scholz, Mark Creamer, Richard Y. Lam, Jeffrey S. Turner, Khang N. Chau, Lauren K. Becker, and Clifford U. Felarca. "Enzalutamide in men with prostate cancer resistant to docetaxel and abiraterone." In *ASCO Annual Meeting Proceedings*, vol. 32, no. 4_suppl, p. 247. 2014.

Drabkin, Harry A., and Jeffrey Turner. "Renal Cancer Pathogenesis." In *Encyclopedia of Cancer*, pp. 3238-3241. Springer Berlin Heidelberg, 2011.

Chaudhary, Uzair B., and Jeffrey S. Turner. "Finasteride." *Expert opinion on drug metabolism & toxicology* 6, no. 7 (2010): 873-881.

Turner, J. S., C. S. Chen, W. Butler, J. Bearden III, E. Garrett-Mayer, G. Onicescu, and A. S. Kraft. "Bortezomib therapy for prostate specific antigen (PSA)-only relapse after definitive local therapy." Abstract. *Journal of Clinical Oncology* 27 (2009).

Turner, Jeffrey, and Uzair Chaudhary. "Dramatic prostate-specific antigen response with activated hemicellulose compound in metastatic castration-resistant prostate cancer." *Anti-cancer drugs* 20, no. 3 (December 2009): 215-216.

Verma, Nitin, John Lazarchick, Vinay Gudena, Jeffrey Turner, and Uzair B. Chaudhary. "Testicular lymphoma: an update for clinicians." *The American journal of the medical sciences* 336, no. 4 (October 2008): 336-341.

Turner, Jeffrey S., Eric M. Cheung, Jaya George, and David I. Quinn. "Pain management, supportive and palliative care in patients with renal cell carcinoma." *BJU international* 99, no. 5b (April 2007): 1305-1312.

Yasin, B., M. Pang, J. S. Turner, Y. Cho, N. N. Dinh, A. J. Waring, R. I. Lehrer, and E. A. Wagar. "Evaluation of the inactivation of infectious herpes simplex virus by host-defense peptides." *European Journal of Clinical Microbiology and Infectious Diseases* 19, no. 3 (March 2000): 187-194.

Lee, S., F. Espin, J. Turner, M. Griswold, and D. Kahn. "Genotyping of HIV-1 drug-resistance: comparison between in-house procedure and visible genetics Trugene [Tm] HIV-1 assay." Abstract. *Abstracts of Conference on Antimicrobial Agents and Chemotherapy* 39 (September 1999): 462.

Cho, Yoon, Jeffrey S. Turner, Nhu-Nguyen Dinh, and Robert I. Lehrer. "Activity of Protegrins against Yeast-Phase *Candida albicans*." *Infection and immunity* 66, no. 6 (June 1998): 2486-2493.

Turner, Jeffrey, Yoon Cho, Nhu-Nguyen Dinh, Alan J. Waring, and Robert I. Lehrer. "Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils." *Antimicrobial agents and chemotherapy* 42, no. 9 (September 1998): 2206-2214.

CLINICAL TRIALS

Sub-investigator

SP005 VIABLE, Phase 3: DVAC Added to Standard Chemotherapy for Men With Metastatic Castrate Resistant Prostate Cancer.

GU12-159 PACIFIC: OGX-427 in Metastatic Castrate-Resistant Prostate Cancer with Prostate-Specific Antigen Progression While Receiving Abiraterone.

ONC-MA-1004 TRUMPET: Observational Cohort Study of Patients with Castrate-Resistant Prostate Cancer on Lupron starting Enzalutamide/Abiraterone.

ARMOR3-SV, Phase 3: Trial of Galeterone in Men with Metastatic Castrate Resistant Prostate Cancer whose Tumors Express the AR-V7 Splice Variant.

P12-1 PREDICT: Observational Study to Evaluate Characteristics Predictive of a Positive Imaging Study for Metastatic Disease in Castrate-Resistant Prostate Cancer.

P11-4 PRIME, Phase 4: Immune Monitoring Protocol in Men with Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T.

XL184-306 COMET-2: Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer (COMET-2).

OGX-011-12 AFFINITY: Comparison of Cabazitaxel/Prednisone Alone or in Combination with Custirsen for 2nd Line Chemotherapy in Prostate Cancer (AFFINITY).

SIPIPI 2013: Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer.

P10-3 PROCEED: A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer (PROCEED).

P11-4 PRIME: Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T (PRIME).